71 results about "Bone marrow cell" patented technology

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

The invention belongs to the technical field of biological genetic engineering, and relates to a high-risk myelodysplastic syndrome screening gene and a diagnostic kit thereof. The invention provides an application of detecting YTHDF2, METTL3 and NAT10 gene expression of bone marrow cells of high-risk MDS patients as a specific molecular marker for screening the high-risk myelodysplastic syndrome, and by detecting mRNA expression levels of the YTHDF2, METTL3 and NAT10 genes, the screening of the patients in the high-risk myelodysplastic syndrome is facilitated. Meanwhile, treatment and prognosis evaluation of patients with high-risk myelodysplastic syndromes can be better guided. Only the bone marrow fluid of the patient needs to be extracted and collected during bone marrow cytology examination of the patient, the patient compliance is good, the bone marrow fluid is selected from human bone marrow fluid mononuclear cells, the detection result is more accurate, and the method is suitable for clinical large-scale application.

Methods, systems, and compositions are provided for extracting bone marrow cells from bone obtained from deceased donors, for preparing the bone marrow for cryopreservation, and for obtaining desired cells from cryopreserved and fresh bone marrow

The invention belongs to the technical field of biological medicine, and particularly relates to a culture method and application of a hematological malignant tumor organoid. The culture method comprises the following steps: S01, obtaining a tumor cell sample; s02, preparing a bone marrow microenvironment simulation matrix, and resuspending tumor cells; s03, a specific culture medium is added for hematoma organoid culture; s04, performing phenotype identification on the cultured hematological malignant tumor organoid; and hematological malignant tumor organs with phenotypes close to those of bone marrow cells of the patient are screened out. According to the method system disclosed by the invention, the hematoma organoid is successfully cultured and is further subjected to phenotype identification, and the screened hematoma organoid is close to the cellular immune phenotype of a patient and can be used for accurate detection of clinical patient drug sensitivity and effective test of potential effective target drugs.

The present invention belongs to the field of biological genetic engineering technology and relates to high-risk myelodysplastic syndrome screening genes and diagnostic kits. The present invention provides an application of detecting the expression of YTHDF2, METTL3, and NAT10 genes in bone marrow cells of high-risk MDS patients as a specific molecular marker for screening high-risk myelodysplastic syndrome. By detecting the expression levels of YTHDF2, METTL3, and NAT10 genes mRNA, it helps to screen patients with high-risk myelodysplastic syndrome and better guide the treatment and prognosis evaluation of patients with high-risk myelodysplastic syndrome. The present invention only needs to extract the patient's bone marrow fluid and collect it together when the patient undergoes bone marrow cytology examination. The patient compliance is good, and the material is taken from human bone marrow fluid mononuclear cells. The test results are more accurate and suitable for large-scale clinical application.

The application discloses a method for establishing a mouse model of MHC haplotype compatible allogeneic hematopoietic cell transplantation, and belongs to the technical field of animal experiment model construction. The technical problem to be solved by the application is how to construct a mouse model which can be used to study the immune reconstruction mechanism and treatment effect evaluation of MHC haplotype compatibility and MHC full compatibility in bone marrow cell transplantation recipient mice. To solve the technical problem, the application provides a method for constructing a mouse model of MHC haplotype compatible allogeneic hematopoietic cell transplantation, which comprises transplanting bone marrow cells of a donor mouse into a recipient mouse, and the MHC haplotype of the donor mouse and the recipient mouse is compatible. The application sets a modeling condition, and the model establishment condition is evaluated by survival condition, graft-versus-host disease and rejection reaction observation, flow cytometry and histopathological section, so as to prove that the model is reliable and stable.

The invention belongs to the field of immunotoxicology, and particularly relates to a method for immunotyping bone marrow cells by flow cytometry. The flow cytometry immune typing method for bone marrow cells comprises the following steps: collecting macaca fascicularis bone marrow fluid, and preparing the macaca fascicularis bone marrow fluid into single-cell suspension; dyeing the obtained cells by using an antibody combination containing a plurality of fluorescent labels; then, a flow cytometer is used for collecting cell fluorescence signals, a standardized gate setting strategy is executed, and based on collected data, the percentage of each cell subset in CD45 + living white blood cells is calculated to complete immune typing. According to the flow cytometry immune typing method for the bone marrow cells, the problems of low efficiency, low repeatability, low sensitivity and poor specificity of related technologies are solved, and more accurate and reliable data support is provided for early discovery, risk assessment and mechanism research of drug immunotoxicity.

The invention discloses an application of fucoidin in preparation of a medicine for preventing or treating radiation-induced leucopenia. The effect of the fucoidin for preventing and treating radiation-induced leucopenia is investigated by measuring the influence of the fucoidin on the five-classification counting of peripheral blood leucocytes, thymus and spleen indexes, the number of bone marrow nucleated cells, the activity of bone marrow cells and the formation number of bone marrow cell colonies of a mouse with radiation-induced leucopenia. A test result shows that the fucoidin has a remarkable curative effect on preventing and treating radiation-induced leucopenia and has no toxic or side effect.

The present invention relates to a computer-implemented method for producing a trained model for detecting one or more defined cell types and / or cellular indicators, such as biomarkers or cellular abnormalities, in particular genomic aberrations, from single-cell images obtained from a sample of a body liquid, bone marrow, cytology smear or slide preparations, in particular a blood smear sample. It relates also to a computer-implemented method for detecting one or more defined cell types and / or cellular indicators, such as biomarkers or cellular abnormalities, in particular genomic aberrations, from single-cell images obtained from a sample of a body liquid, bone marrow or cytology smear, in particular a blood smear sample.

The present invention relates to a method of identifying rejuvenating factor(s) by culturing bone marrow cells wherein age-specific human serum is added to the bone marrow cells and to a method of testing active agents to augment the effect of the one or more rejuvenating factor(s) identified.

Methods, systems, and compositions are provided for extracting bone marrow cells from bone obtained from deceased donors, for preparing the bone marrow for cryopreservation, and for obtaining desired cells from cryopreserved and fresh bone marrow.

This invention discloses a bone marrow cell paraffin block, its preparation method, and its application, belonging to the field of pathological detection technology. The preparation method includes the following steps: Red blood cell lysis: Bone marrow aspirate is taken, and a precipitate containing cells and sediment is separated. A red blood cell lysis agent is added to lyse the red blood cells, and a lysed precipitate containing unlysed cells and sediment is separated. Formation: The lysed precipitate is resuspended in formalin solution for fixation, the supernatant is removed, and the precipitate is resuspended in agar solution. The agar is cooled and solidified, and then fixed again in neutral formalin. Dehydration: The solidified agar block is dehydrated. Embedding: The dehydrated agar block is embedded in paraffin to form a paraffin block. The cell paraffin block prepared by this method can supplement the diagnosis when bone marrow smears or bone marrow biopsy samples are not ideally prepared.

The invention discloses a high-bionic in-vivo immune microenvironment in-vitro skin model and application, and belongs to the technical field of biological medicine. The preparation method of the in-vitro skin model of the high-bionic in-vivo immune microenvironment comprises the following steps: firstly, adding a culture medium into the lower layer of a six-pore plate, then adding a mouse bone marrow cell suspension, then putting the six-pore plate into a Transwell chamber, flatly laying separated mouse skin on an absorptive gelatin sponge, putting the absorptive gelatin sponge into the Transwell chamber, adding the culture medium into the Transwell chamber, and then putting the mouse skin into the transwell chamber to obtain the in-vitro skin model of the high-bionic in-vivo immune microenvironment. Placing the six-hole plate in a cell incubator for culturing to obtain the in-vitro skin model. According to the in-vitro skin-bone marrow cell co-culture system, an immune environment is provided for the in-vitro skin by introducing bone marrow cells, so that the culture environment of the in-vitro skin is more complete, the difficulties that cell components are simple and the immune environment is deficient at present can be solved, and the in-vitro skin-bone marrow cell co-culture system is more in line with the 3R principle and is high in bionic property and low in cost.

The bone marrow cell morphology analysis system provided by this invention includes a base, a feeding module mounted on the base, and a detection module mounted on the base to one side of the feeding module. The feeding module includes a slide holder and a slide conveying mechanism, and the detection module includes a microscope and a slide placement platform. The slide conveying mechanism can automatically transport slides from the slide holder to the slide placement platform located below the microscope. After the sample on the slide is detected by the microscope, the slide conveying mechanism automatically returns the slide to the slide holder. The entire process can achieve fully automated operation, which not only greatly improves the efficiency of sample detection, but also helps to ensure the accuracy of each test result because it uses mechanical operation.

The present application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for reducing adverse reactions after radiotherapy and chemotherapy of tumor patients and a preparation method thereof, comprising the following components in parts by weight: Radix Bupleuri 6-9 parts, Radix Paeoniae Alba 6-9 parts, Rhizoma Atractylodis Macrocephalae 6-9 parts, Poria 6-9 parts, Angelica sinensis 6-9 parts, Zingiber officinale 3 parts, Radix Rehmanniae Recens 3-6 parts, Gardenia 3-6 parts, Radix Paeoniae Rubra 3-6 parts, Radix Paeoniae Alba 12-20 parts, Rhizoma Chuanxiong 6 parts, and Radix Glycyrrhizae 3-6 parts; the traditional Chinese medicine composition can improve the spirit and movement state of mice, and the weight and food intake of mice are obviously increased, the number of dead mice is significantly reduced, and the tumor volume and weight of mice are significantly reduced; the spleen and thymus indexes, the number of white blood cells, red blood cells and platelets in peripheral blood, and the hemoglobin content are all significantly increased; the number of bone marrow cells and the CD4 + T / CD8 + T cell ratio in peripheral blood are all significantly increased; when applied to clinical patients, the traditional Chinese medicine composition can reduce adverse reactions after radiotherapy and chemotherapy of tumor patients, and has a broad application prospect.

The present invention discloses a method for constructing a conditional knockout mouse model of the Cpt1a gene and its application. The construction method is to construct a lupus erythematosus mouse model by conditionally knocking out the Cpt1a gene in macrophages. The construction method of the lupus erythematosus mouse model provided by the present invention realizes the knockout of the Cpt1a gene in the bone marrow cell lineage, while the gene is normally expressed in other tissues or cells. It is a simple, efficient and rapid construction method. The obtained lupus erythematosus mouse model can be better applied to the mechanism research of lupus erythematosus, and the preparation and / or screening of drugs for treating lupus erythematosus.

The invention discloses a bone marrow smear preparation method based on air source purging, system equipment and a medium, and relates to the technical field of medical examination and cell preparation, and the method comprises the following steps: obtaining and processing a bone marrow cell sample to form a cell suspension; applying the cell suspension to a glass slide, and performing directional treatment on the cell suspension in an air source purging manner; fixing and dyeing the bone marrow smear which is formed by blowing through an air source, so as to complete the smear preparation operation of the bone marrow smear. According to the method, smear quality fluctuation caused by sample state difference is remarkably reduced, a uniform basic suspension condition is provided for stable development of subsequent airflow purging, smear preparation consistency and reproducibility are optimized from the source, smear region distribution quality improvement and stable acquisition of morphological analysis results are achieved, and the method is suitable for large-scale popularization and application. The dyeing uniformity and the color development consistency are improved, and better effects are achieved in the aspects of cell resuspension uniformity, cell spreading consistency and film production process standardization.

The application discloses a bone marrow morphology acute event identification early warning system and relates to the technical field of intelligent medical treatment, and the technical solution points are as follows: acquiring bone marrow cell image data, pre-processing, obtaining pre-processed image data; inputting the pre-processed image data into a trained AI model, and outputting a classification prediction result. The application can more accurately identify and classify bone marrow cells by applying a visual Transformer and a visual Mamba model, can identify different cell development stages, and can diagnose various blood diseases through an AI model standardized analysis process, reduce professional barriers in the field of bone marrow morphology, reduce absolute dependence on expert experience, and enable areas with insufficient medical conditions to also obtain high-quality preliminary diagnosis.

Fibrinogen-coated Albumin Nanospheres (FAS) has shown that it can mobilize bone marrow cells into the blood which then go to injured soft and hard tissues to achieve accelerated repair. It is hypothesize that (a) brain injuries caused by low-dose irradiation under simulated microgravity can be mitigated by the administration of FAS; and (b) the mechanism is from acceleration of neo-vascularization, proven by lineage study of GFP-labeled bone marrow cells implanted into compatible non-GFP animals before injury, which regenerate into functional GFP-brain cells after FAS treatment.

The invention discloses application of colla corii asini bone-strengthening oral liquid to prevention and / or treatment of anemia, and belongs to the technical field of medicines, and the anemia comprises iron-deficiency anemia, renal anemia and myelosuppression anemia. The colla corii asini bone strengthening oral liquid can increase erythrocyte count, hemoglobin concentration, hematocrit, erythrocyte average hemoglobin amount, erythrocyte average hemoglobin concentration and / or erythrocyte average volume; the serum iron content is increased; a transporter divalent metal transporter and a membrane iron transporter are increased; the intestinal iron absorption is promoted. The composition specifically comprises urea nitrogen and creatinine; related indexes of renal anemia are improved; the immune index of renal anemia can be improved. The percentage of leukocytes and lymphocytes of anemia caused by myelosuppression can be recovered; the hemoglobin content is increased; the number of macrophage colony stimulating factors and / or bone marrow cells in serum is increased; the immunocompetence is improved; the proliferation of lymphoid B cells and macrophages is promoted.

Provided are methods and compositions conditioning a patient for an allogeneic transplantation, wherein the patient's hematopoietic stem cells (HSCs) are depleted with an HSC-depleting composition and the patient is then administered allogeneic cells selected from bone marrow cells, umbilical cord blood cells, hematopoietic stem and progenitor cells (HSPCs), peripheral blood CD34+ cells, and peripheral blood CD34+ and CD90+ cells; optionally the patient is also administered a medicament selected from the group consisting of a T-cell depleting or inhibiting antibody or antibody fragment, NK-cell depleting or inhibiting antibody or antibody fragment, immunosuppressive drug, and any combination thereof. The HSC-depleting composition comprises a compound selected from the group consisting of: an antibody or antibody fragment with specific binding affinity to a protein displayed at the HSC surface, a conjugate comprising an HSC-recognition molecule and a toxin, and any combination thereof.

The present invention relates to engineered SIRP alpha variants and methods of use thereof. Signal regulatory protein a (SIRPa) is a regulatory membrane glycoprotein of the SIRP family. The protein is mainly expressed by bone marrow cells and also expressed by stem cells or neurons. SIRPa is used as an inhibitory receptor and interacts with a widely expressed transmembrane protein CD47. The present disclosure relates to engineered SIRPa variants and methods of use thereof.

The present application relates to the field of flow cytometry, in particular to a flow cytometry kit and a monitoring method for monitoring acute B lymphocyte leukemia minimal residual disease, the kit comprises 15 antibodies, aiming at the development mode of bone marrow B cells and common abnormal expression of ALL-B, combined with a full spectrum flow cytometer, all the above detections can be completed by one tube panel, which is convenient, fast, time-saving and labor-saving, and simple to operate.

The present invention belongs to the field of biomedicine technology, and specifically relates to a method and application for culturing organoids of hematological malignancies. The culturing method of the present invention comprises: S01: obtaining a tumor cell sample; S02: preparing a bone marrow microenvironment-simulating matrix and resuspending the tumor cells; S03: adding a specific culture medium to culture hematological malignant tumor organoids; S04: phenotypic identification of the cultured hematological malignant tumor organoids; and screening out hematological malignant tumor organoids that are close to the patient's bone marrow cell phenotype. The method system of the present invention not only successfully cultured hematological malignant tumor organoids, but also further performed phenotypic identification on them. The screened hematological malignant tumor organoids are close to the patient's cell immune phenotype and can be used for accurate detection of clinical patient drug sensitivity and effective testing of potentially effective target drugs.

Provided are methods and compositions conditioning a patient for an allogeneic transplantation, wherein the patient's hematopoietic stem cells (HSCs) are depleted with an HSC-depleting composition and the patient is then administered allogeneic cells selected from bone marrow cells, umbilical cord blood cells, hematopoietic stem and progenitor cells (HSPCs), peripheral blood CD34+cells, and peripheral blood CD34+ and CD90+ cells; optionally the patient is also administered a medicament selected from the group consisting of a T-cell depleting or inhibiting antibody or antibody fragment, NK-cell depleting or inhibiting antibody or antibody fragment, immunosuppressive drug, and any combination thereof. The HSC-depleting composition comprises a compound selected from the group consisting of: an antibody or antibody fragment with specific binding affinity to a protein displayed at the HSC surface, a conjugate comprising an HSC-recognition molecule and a toxin, and any combination thereof.

The invention discloses a self-adaptive fixing bone marrow assembly type separating device which comprises a collecting pipe, a separating pipe and a core which are assembled and installed, a fixing hole channel in the core is used for fixing bones, and incomplete assembly is formed between the separating pipe and the core through a wedge-shaped key block and a wedge-shaped key groove. After interaction force is generated between the wedge-shaped key block and the wedge-shaped key groove, the core and the fixing hole channel of the core are extruded and deformed to tightly extrude the bone to be fixed, and a liquid carrying interval is formed. By adopting an assembly type centrifugal bone marrow separation mode, after the core and the separation pipe are assembled, interaction force which is positively correlated with the centrifugal rotating speed is generated between the wedge-shaped key block and the wedge-shaped key groove, so that the fixed hole channel of the core generates deformation quantity which is positively correlated with the centrifugal rotating speed, and the bone fixed in the core is tightly extruded; and a liquid carrying interval capable of being pre-filled with flushing liquid is formed, so that centrifugal self-adaptive fixation of bones and integration of flushing and centrifugal separation are achieved, the collection rate of bone marrow is effectively increased, and the inactivation rate of bone marrow cells is effectively reduced.

The invention relates to the crossing field of medical image processing and artificial intelligence technology, in particular to a bone marrow cell morphology artificial intelligence analysis method and system, and the method comprises the steps: obtaining a multi-view high-resolution image of a bone marrow smear and / or a peripheral blood smear under the oil immersion magnification, and carrying out the preprocessing; carrying out red blood cell coarse segmentation and fine classification through a cascade deep network, and identifying target-shaped, broken, teardrop-shaped and elliptical red blood cells; correcting broken red blood cell counting by adopting a fragment aggregation correction algorithm; and calculating an MCI value in combination with blood routine test data, and carrying out weighted fusion on the MCI value and the abnormal red blood cell proportion to generate a thalassemia screening comprehensive score. Therefore, the problems of low manual identification efficiency, insufficient abnormal red blood cell identification accuracy, large broken red blood cell counting deviation, difficulty in distinguishing multiple types of abnormal red blood cells, lack of organic combination with clinical diagnosis indexes and the like are solved, and the efficiency and accuracy of morphological analysis of bone marrow cells are improved; and a reliable basis is provided for diagnosis of diseases such as thalassemia.

The present disclosure relates to use of an oligosaccharide or a glucosidase to enhance protein expression from synthetic RNA delivered by injection. In particular, the present disclosure relates to use of chitosan or hyaluronidase to transfect skeletal muscle or skin cells. Other cells that can be effectively transfected with synthetic RNA / chitosan mixtures include bone marrow cells, peritoneal cavity cells, and retro-orbital sinus cells.

The present invention relates to a computer-implemented method for producing a trained model for detecting one or more defined cell types and / or cellular indicators, such as biomarkers or cellular abnormalities, in particular genomic aberrations, from single-cell images obtained from a sample of a body liquid, bone marrow, cytology smear or slide preparations, in particular a blood smear sample. It relates also to a computer-implemented method for classifying a sample of a body liquid, bone marrow or cytology smear, in particular a blood smear sample, as indicative or non-indicative of one or more defined cell types and / or cellular indicators, such as biomarkers or cellular abnormalities, in particular genomic aberrations, from single-cell images obtained from the sample.

The invention relates to the technical field of medical image processing, in particular to a blood disease classification-oriented bone marrow cell multi-scale identification method, which comprises the following steps of: constructing and training a bone marrow cell identification model, and inputting an image to be identified into the trained bone marrow cell identification model to obtain an identification result; the bone marrow cell recognition model comprises a hierarchical feature extraction module, a feature enhancement module, a class center learning framework module and a multi-layer perceptron; compared with an existing model, the classification number and accuracy of cell classification are improved, preliminary diagnosis of hematologic tumor diseases can be achieved in an auxiliary mode, and the examination time is shortened.